These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34519594)

  • 1. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
    Zeng L; Yang K; Wu Y; Yu G; Yan Y; Hao M; Song T; Li Y; Chen J; Sun L
    J Autoimmun; 2024 Sep; 148():103291. PubMed ID: 39146891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telitacicept: First Approval.
    Dhillon S
    Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telitacicept for autoimmune nephropathy.
    Cai J; Gao D; Liu D; Liu Z
    Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticytokine therapy impacting on B cells in autoimmune diseases.
    Daridon C; Burmester GR; Dörner T
    Curr Opin Rheumatol; 2009 May; 21(3):205-10. PubMed ID: 19346949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
    Ma X; Fu X; Cui B; Lin H
    Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
    Shivakumar L; Ansell S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
    Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
    PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
    Baert L; Manfroi B; Casez O; Sturm N; Huard B
    J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.
    Jagessar SA; Heijmans N; Oh L; Bauer J; Blezer EL; Laman JD; Migone TS; Devalaraja MN; 't Hart BA
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):557-70. PubMed ID: 22870852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
    Qin Q; Chang Y; Wang D; Wu Y; Zhang LL; Wei W
    Int Immunopharmacol; 2011 Dec; 11(12):2167-75. PubMed ID: 21996540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF: a local and systemic target in autoimmune diseases.
    Moisini I; Davidson A
    Clin Exp Immunol; 2009 Nov; 158(2):155-63. PubMed ID: 19737141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).
    Stohl W
    Arthritis Res Ther; 2010; 12(2):111. PubMed ID: 20441604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
    Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
    Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
    Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
    Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.